Washington, D.C. – In response to recent interest in non-invasive prenatal screenings (NIPS) and their use by patients and health care providers, ACLA has issued the ... Read More
Washington, D.C. – ACLA issued the following statement in response to delayed Congressional action to replenish the depleted COVID-19 Uninsured Relief Fund: “ACLA is committed ... Read More
Washington, D.C. – ACLA Board Chair William G. Morice, MD, PhD, and President of Mayo Clinic Laboratories, today announced the Board’s selection of Susan Van Meter ... Read More
Genetic variations in viruses are a common occurrence that naturally take place over time and can lead to the emergence of new variants with different ... Read More
WASHINGTON, D.C. – Following the Senate confirmation of Robert Califf, M.D. as Commissioner of the U.S. Food and Drug Administration (FDA), the American Clinical Laboratory ... Read More
For the past two years, ACLA has emphasized how a sustainable testing strategy will help the country see a clear end to the pandemic and continues to ... Read More
Washington, D.C. – As cases of COVID-19 continue to surge across the country amid the current Omicron wave, ACLA issued the following statement: “Since the outset of ... Read More
The following is ACLA’s submitted response to the New York Times’ January 1, 2022 Article on Non-Invasive Prenatal Testing (NIPT). The Times’ Jan. 1 article presents a ... Read More
